Laurus Labs concludes successful USFDA audit for API Manufacturing Facility at Hyderabad

Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company in India is pleased to announce the successful completion of the US Food and Drug Administration (US FDA) audit of its API manufacturing facility at Hyderabad. The audit concluded with zero Form 483 observations, reaffirming Laurus Labs commitment to maintaining the highest standards of quality, safety, and compliance.

The US FDA inspection, conducted from 9th to 13th September, focused on evaluating the facility's adherence to global regulatory requirements and best practices. Laurus Labs' API manufacturing facility, located at DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana is instrumental in developing Active Pharmaceutical Ingredients, bolstering the company's ability to deliver high-quality, innovative pharmaceutical solutions to its global customers.

Shares of Laurus Labs Limited was last trading in BSE at Rs. 505.70 as compared to the previous close of Rs. 506.95. The total number of shares traded during the day was 48404 in over 1393 trades.

The stock hit an intraday high of Rs. 511.40 and intraday low of 503.00. The net turnover during the day was Rs. 24585089.00.

Source : Equity Bulls

Keywords

LaurusLabs INE947Q01028 Pharmaceuticals USFDA Audit SuccessfulCompletion ZeroForm483 APIManufacturingFacility Hyderabad